Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA

• Main Authors: Francisco José Toja-Camba (Author), Laura García-Quintanilla (Author), Lorena Rodríguez-Martinez (Author), Julia Tomine (Author), Francisco Cajade-Pascual (Author), Carolina Feitosa (Author), Irene Zarra-Ferro (Author), Manuel Barreiro- (Author), Jaime González-López (Author), Cristina Mondelo-García (Author), Anxo Fernández-Ferreiro (Author)
• Format: Book
• Published: MDPI AG, 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The introduction of point-of-care (POC) assays into clinical practice in patients with inflammatory disease enables on-demand therapeutic decision making. The aim of this study was to compare the POC test Quantum blue (Bühlmann Laboratories) for infliximab (IFX), adalimumab (ADL), and its anti-drug...